X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES WYETH LTD VENUS REMEDIES/
WYETH LTD
 
P/E (TTM) x -3.7 27.7 - View Chart
P/BV x 0.1 5.3 2.6% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 VENUS REMEDIES   WYETH LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
WYETH LTD
Mar-13
VENUS REMEDIES/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs1261,044 12.1%   
Low Rs61818 7.5%   
Sales per share (Unadj.) Rs301.8298.6 101.1%  
Earnings per share (Unadj.) Rs-24.957.2 -43.4%  
Cash flow per share (Unadj.) Rs2.558.4 4.4%  
Dividends per share (Unadj.) Rs017.00 0.0%  
Dividend yield (eoy) %01.8 0.0%  
Book value per share (Unadj.) Rs293.3249.5 117.6%  
Shares outstanding (eoy) m12.3422.72 54.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.1 9.9%   
Avg P/E ratio x-3.816.3 -23.1%  
P/CF ratio (eoy) x36.715.9 230.5%  
Price / Book Value ratio x0.33.7 8.5%  
Dividend payout %029.7 0.0%   
Avg Mkt Cap Rs m1,15421,157 5.5%   
No. of employees `0000.90.5 188.0%   
Total wages/salary Rs m393400 98.3%   
Avg. sales/employee Rs Th4,026.113,787.4 29.2%   
Avg. wages/employee Rs Th425.0813.0 52.3%   
Avg. net profit/employee Rs Th-331.82,643.3 -12.6%   
INCOME DATA
Net Sales Rs m3,7246,783 54.9%  
Other income Rs m23353 6.4%   
Total revenues Rs m3,7477,136 52.5%   
Gross profit Rs m3951,617 24.4%  
Depreciation Rs m33827 1,271.8%   
Interest Rs m3546 6,441.8%   
Profit before tax Rs m-2751,938 -14.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m32632 5.0%   
Profit after tax Rs m-3071,301 -23.6%  
Gross profit margin %10.623.8 44.5%  
Effective tax rate %-11.532.6 -35.2%   
Net profit margin %-8.219.2 -43.0%  
BALANCE SHEET DATA
Current assets Rs m2,6386,984 37.8%   
Current liabilities Rs m2,3052,056 112.1%   
Net working cap to sales %8.972.6 12.3%  
Current ratio x1.13.4 33.7%  
Inventory Days Days13599 136.4%  
Debtors Days Days4624 193.5%  
Net fixed assets Rs m4,871244 1,993.8%   
Share capital Rs m123227 54.3%   
"Free" reserves Rs m3,4965,441 64.2%   
Net worth Rs m3,6195,668 63.9%   
Long term debt Rs m1,37425 5,497.6%   
Total assets Rs m7,5097,901 95.0%  
Interest coverage x0.2353.3 0.1%   
Debt to equity ratio x0.40 8,610.0%  
Sales to assets ratio x0.50.9 57.8%   
Return on assets %0.616.5 3.8%  
Return on equity %-8.522.9 -37.0%  
Return on capital %1.634.0 4.6%  
Exports to sales %00.2 0.0%   
Imports to sales %13.936.3 38.2%   
Exports (fob) Rs mNA15 0.0%   
Imports (cif) Rs m5172,465 21.0%   
Fx inflow Rs m015 0.0%   
Fx outflow Rs m5172,677 19.3%   
Net fx Rs m-517-2,662 19.4%   
CASH FLOW
From Operations Rs m514923 55.7%  
From Investments Rs m-123317 -38.8%  
From Financial Activity Rs m-387-481 80.5%  
Net Cashflow Rs m4759 0.6%  

Share Holding

Indian Promoters % 32.9 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 0.2 11.3 1.6%  
FIIs % 0.6 7.2 8.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 30.4 218.4%  
Shareholders   20,121 21,978 91.6%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   AUROBINDO PHARMA  MERCK LTD  GSK PHARMA  J.B.CHEMICALS  ORCHID PHARMA LTD  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Flat; IT & Energy Stocks Gain(Closing)

Indian share markets traded on a volatile note throughout the day and ended their session on a flat note. Sectoral indices ended on a mixed note with stocks in the IT sector.

Related Views on News

VENUS REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of VENUS REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of VENUS REMEDIES. Also includes updates on the valuation of VENUS REMEDIES.

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Our First Bluechip Stock Recommendation in Smart Money Secrets(The 5 Minute Wrapup)

Jan 9, 2019

For the first time, we have recommended a bluechip stock in Smart Money Secrets.

3 Stocks in Super Investor Sumeet Nagar's Portfolio That You Can Buy Right Now(The 5 Minute Wrapup)

Jan 11, 2019

The reasons that make these six stocks in Sumeet Nagar's portfolio so compelling

Follow a Super Investor Like This to Multiply Your Wealth(The 5 Minute Wrapup)

Jan 4, 2019

Following a super investor can certainly help build a portfolio and create wealth in the long term.

15 Mistakes to Avoid to Make a Killing in the Markets(Profit Hunter)

Jan 3, 2019

Richa dissects the common mistakes investors make and how to avoid and even take advantage of them.

My First Stock Trading Recommendation For 2019(Profit Hunter)

Jan 10, 2019

My first trading recommendation for 2019 is a bluechip auto stock. Find out everything about it right away.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jan 16, 2019 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS